Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Colitis, Ulcerative 3Urogenital Neoplasms 2Inflammatory Bowel Diseases 2Crohn Disease 2Colitis 2Carcinoma, Non-Small-Cell Lung 2Takayasu Arteritis 1Recurrence 1Melanoma 1Lung Neoplasms 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

Infliximab 5Tea 3Polyethylene Glycols 3Blood Specimen Collection 3Standard of Care 2MEDI2070 2Lidocaine 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Colonoscopy 2CT-P13 2Biopsy 2Adalimumab 2sodium phosphate 1purine 1prucalopride 1polyethylene glycol 400 1picosulfate sodium 1golimumab 1fumaric acid 1cabozantinib 1Tumor Necrosis Factor Inhibitors 1Thrombin Time 1Surveys and Questionnaires 1Surgical Tape 1Sulfasalazine 1Spectrum Analysis, Raman 1Specimen Handling 1Single-Balloon Enteroscopy 1Registries 1Proctocolectomy, Restorative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Inflammatory Bowel Diseases × CT-P13 × Clear all
NCT04646187 2025-01-06

FREE

University Medical Center Groningen

Phase 4 Enrolling by invitation
148 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

NCT03452501 2021-02-23

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Hikma Pharmaceuticals LLC

Completed
157 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡